Nascent Biotech Inc. (NBIO)
| Market Cap | 7.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.37M |
| Shares Out | 97.06M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $0.0779 |
| Previous Close | $0.0746 |
| Change ($) | 0.0033 |
| Change (%) | 4.42% |
| Day's Open | 0.0749 |
| Day's Range | 0.0710 - 0.0780 |
| Day's Volume | 242,157 |
| 52-Week Range | 0.0437 - 0.1950 |
SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...
SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mo...
SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mon...
Nascent Biotech Inc (OTCMKTS: NBIO) has announced the publication of promising in-vitro study results from its pritumumab (PTB) research collaboration with Syracuse University, validating the potential ...
About NBIO
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company has a research collaboration agreement with Manhattan BioSolutions, Inc. to initiate a vaccine program for the prevention of COVID-19 or other viral infections; an... [Read more...]
| Industry Biotechnology | |
| Stock Exchange OTCMKTS | Ticker Symbol NBIO |